Reporting Avenues for Concerns Related to Integrity or Fairness

The Innovative Immunology (AIDC (10)) study section reviews small business (SBIR/STTR) applications that address basic and applied immunology, immunologic therapies, and diseases of immunologic origin.

Note: the scope DCAI (10) will be modified after the December 2022 review meeting.

Review Dates

Topics


  • Immunoassays and immunologic markers: development of diagnostic tests and reagents for transplantation, neoplastic diseases, and autoimmune diseases
  • Immunotherapeutic regimens: for transplantation, neoplastic diseases, autoimmune and immune mediated diseases, including allergy, diabetes, muscular sclerosis, systemic lupus erythematosus
  • Antibodies: use of available polyclonal and monoclonal antibodies as therapeutics for immunologic diseases
  • Cellular immune system: reagents for identification, characterization, and modulation of B lymphocytes, T lymphocytes, dendritic cells, eosinophils, stem cells, bone marrow, lymph nodes, mast cells, antigen-presenting cells, cytotoxic cells
  • Innate immune system: reagents for identification, characterization, and modulation of complement, monocytes, macrophages, neutrophils, basophils, mast cells, natural killer cells, and innate T cells
  • Immunomodulation of the immune system interactions: suppression, enhancement, biologics including adjuvants, cytokines, small molecules, proteins/peptides

Shared Interests and Overlaps:

There are shared interests with Microbial Vaccine Development [DCAI (11)] for small business applications developing vaccines and the evaluation of immune responses. Applications focusing on infectious agents may be reviewed in DCAI (11), while those not related to microorganisms may be reviewed here.

There are shared interests with Diabetes, Metabolism, Nutrition and Obesity [EMS (10)] for small business applications examining type 1 diabetes onset and progression. Applications addressing the endocrine, metabolic and nutritional basis of diabetes and obesity may be reviewed in EMS (10), while those that address lymphocyte destruction of pancreatic beta cells and insulin deficiency, as well as anti-inflammatory agents, and stem cell replacement for diabetes may be reviewed here.

There are shared interests with Biological Chemistry, Biophysics, and Assay Development [MCST (10)] for small business applications using technologies and methods for immunological, enzymatic, or oligonucleotide sensors and reporters for bioassays and diagnostics. Applications addressing disease-agnostic assay development, biochemistry and protein engineering, including producing synthetic antibodies, may be reviewed in MCST (10), while those that use bioassays and diagnostics for immunoassays and immunologic markers, including development of diagnostic tests and reagents for transplantation, neoplastic diseases, and autoimmune diseases may be reviewed here.

There are shared interests with Cell and Molecular Biology [MCST (15)] for small business applications developing new technologies for cell culture, separations, and sorting, including flow cytometry and stem cells. Applications addressing technology development in cellular cultures, assays, measurements, and imaging, or technology development in genetic assays, diagnostics, sequencing, and engineering may be reviewed in MCST (15), while those that address the sorting and flow cytometry of immune cells for identification, characterization, and modulation of monocytes, macrophages, neutrophils, basophils, mast cells, natural killer cells and T and B cells may be reviewed here.

There are shared interests with Dermatology, Rheumatology and Inflammation [MSOS (10)] for small business applications advancing the assessment and treatment of auto-immune and immune-mediated skeletal muscle, rheumatic and skin diseases. Applications that focus on the use of immunological therapies to treat immune-mediated diseases that affect the skin, muscle, bone, and joints may be reviewed in MSOS (10). Applications that focus on the immunological aspects of these diseases, including development of immunotherapies, are reviewed here.

There are shared interests with Respiratory Sciences [RCCS (11)] for small business applications addressing the development of therapeutics that are focused on the pulmonary system and related organs. Applications addressing diagnostics, medical devices and therapeutics that are focused on the entire pulmonary system and related organs may be reviewed in RCCS (11), while those examining immunotherapeutic regimens for asthma and allergic diseases may be reviewed here.

There are shared interests with small business panels in the Cancer Diagnosis, Prevention & Therapeutics (CDPT) Review Branch. Small business applications addressing experimental therapy for neoplastic diseases in in vitro and in vivo model systems may be reviewed in the CDPT Branch, while applications examining effector:regulatory immune cell imbalance and central and peripheral tolerance in tumor and transplant models may be reviewed here.